Danxin Wang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5810001/publications.pdf

Version: 2024-02-01

86	5,519	109321 35	79698 73
papers	citations	h-index	g-index

87	87	87	7217
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clinical Pharmacology and Therapeutics, 2015, 98, 19-24.	4.7	491
2	Allelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G. Journal of Biological Chemistry, 2005, 280, 32618-32624.	3.4	490
3	Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenetics and Genomics, 2005, 15, 693-704.	1.5	419
4	Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics Journal, 2011, 11, 274-286.	2.0	412
5	Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20552-20557.	7.1	378
6	Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood, 2008, 112, 1013-1021.	1.4	187
7	Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenetics and Genomics, 2005, 15, 693-704.	1.5	166
8	Opioid Receptor Homo- and Heterodimerization in Living Cells by Quantitative Bioluminescence Resonance Energy Transfer. Molecular Pharmacology, 2005, 67, 2173-2184.	2.3	142
9	Intronic Polymorphisms Affecting Alternative Splicing of Human Dopamine D2 Receptor Are Associated with Cocaine Abuse. Neuropsychopharmacology, 2011, 36, 753-762.	5.4	128
10	Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain, 2009, 132, 417-425.	7.6	123
11	Inverse agonists and neutral antagonists at Âµâ€Šopioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. Journal of Neurochemistry, 2001, 77, 1590-1600.	3.9	118
12	Calmodulin Binding to G Protein-coupling Domain of Opioid Receptors. Journal of Biological Chemistry, 1999, 274, 22081-22088.	3.4	114
13	Î¼-Opioid Receptor-mediated ERK Activation Involves Calmodulin-dependent Epidermal Growth Factor Receptor Transactivation. Journal of Biological Chemistry, 2001, 276, 33847-33853.	3.4	113
14	Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Human Molecular Genetics, 2014, 23, 268-278.	2.9	101
15	Searching for polymorphisms that affect gene expression and mRNA processing: Example ABCB1 (MDR1). AAPS Journal, 2006, 8, E515-E520.	4.4	92
16	Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. Pharmacogenetics and Genomics, 2008, 18, 781-791.	1.5	90
17	Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Life Sciences, 2005, 76, 1427-1437.	4.3	88
18	Polymorphisms affecting gene regulation and mRNA processing: Broad implications for pharmacogenetics. , 2005, 106, 19-38.		83

#	Article	IF	Citations
19	Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues. Pharmacogenetics and Genomics, 2006, 16, 735-745.	1.5	83
20	Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset. Human Molecular Genetics, 2014, 23, 1957-1963.	2.9	82
21	In Vivo Characterization of 6Î²-Naltrexol, an Opioid Ligand with Less Inverse Agonist Activity Compared with Naltrexone and Naloxone in Opioid-Dependent Mice. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 1150-1162.	2.5	80
22	Different Effects of Opioid Antagonists on Î¼-, Î´-, and Îº-Opioid Receptors with and without Agonist Pretreatment. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 544-552.	2.5	80
23	Basal Signaling Activity of Î¼ Opioid Receptor in Mouse Brain: Role in Narcotic Dependence. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 512-520.	2.5	77
24	CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing. Pharmacogenetics and Genomics, 2016, 26, 40-43.	1.5	76
25	G-protein coupling of Î¼-opioid receptors (OP3): elevated basal signalling activity. Biochemical Journal, 2000, 348, 531-537.	3.7	69
26	Single Nucleotide Polymorphisms in the Human Î¼ Opioid Receptor Gene Alter Basal G Protein Coupling and Calmodulin Binding. Journal of Biological Chemistry, 2001, 276, 34624-34630.	3.4	67
27	KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenetics and Genomics, 2007, 17, 719-729.	1.5	65
28	Allele-specific tumor spectrum in Pten knockin mice. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5142-5147.	7.1	59
29	Cholesteryl Ester Transfer Protein (CETP) Polymorphisms Affect mRNA Splicing, HDL Levels, and Sex-Dependent Cardiovascular Risk. PLoS ONE, 2012, 7, e31930.	2.5	59
30	CACNA1CGene Polymorphisms, Cardiovascular Disease Outcomes, and Treatment Response. Circulation: Cardiovascular Genetics, 2009, 2, 362-370.	5.1	58
31	Nicotinic Î±5 receptor subunit mRNA expression is associated with distant 5â€² upstream polymorphisms. European Journal of Human Genetics, 2011, 19, 76-83.	2.8	58
32	Functional characterization of CYP2D6 enhancer polymorphisms. Human Molecular Genetics, 2015, 24, 1556-1562.	2.9	58
33	Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity. Pharmacogenetics and Genomics, 2011, 21, 652-664.	1.5	44
34	Genetic variations in human G protein-coupled receptors: Implications for drug therapy. AAPS PharmSci, 2001, 3, 54-80.	1.3	42
35	Nuclear Ca2+/Calmodulin Translocation Activated by Î¼-Opioid (OP3) Receptor. Journal of Neurochemistry, 2002, 74, 1418-1425.	3.9	40
36	Calmodulin Regulation of Basal and Agonist-Stimulated G Protein Coupling by the Î¼-Opioid Receptor (OP3) in Morphine-Pretreated Cell. Journal of Neurochemistry, 2002, 75, 763-771.	3.9	38

#	Article	IF	Citations
37	TheCHRNA5/CHRNA3/CHRNB4Nicotinic Receptor Regulome: Genomic Architecture, Regulatory Variants, and Clinical Associations. Human Mutation, 2017, 38, 112-119.	2.5	34
38	Promoter Polymorphisms in ACE (Angiotensin Iâ€“Converting Enzyme) Associated With Clinical Outcomes in Hypertension. Clinical Pharmacology and Therapeutics, 2009, 85, 36-44.	4.7	33
39	Differential Effects of Î¼-Opioid Receptor Ligands on Ca2+Signaling. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 1002-1012.	2.5	32
40	Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients. BMC Medical Genomics, 2012, 5, 32.	1.5	30
41	Regulatory polymorphisms in CYP2C19 affecting hepatic expression. Drug Metabolism and Drug Interactions, 2013, 28, 23-30.	0.3	28
42	G-protein coupling of Î¼-opioid receptors (OP3): elevated basal signalling activity. Biochemical Journal, 2000, 348, 531.	3.7	27
43	Ligand-Free Estrogen Receptor Î± (ESR1) as Master Regulator for the Expression of CYP3A4 and Other Cytochrome P450 Enzymes in the Human Liver. Molecular Pharmacology, 2019, 96, 430-440.	2.3	26
44	Genotyping panel for assessing response to cancer chemotherapy. BMC Medical Genomics, 2008, 1, 24.	1.5	24
45	3-Isobutyl-1-methylxanthine inhibits basal Î¼-opioid receptor phosphorylation and reverses acute morphine tolerance and dependence in mice. European Journal of Pharmacology, 1999, 371, 1-9.	3.5	22
46	The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy. Journal of Personalized Medicine, 2012, 2, 175-191.	2.5	22
47	Calmodulin Binding to Peptides Derived from the i3 Loop of Muscarinic Receptors. Pharmaceutical Research, 2006, 23, 647-653.	3.5	21
48	CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (*2 allele). Pharmacogenetics and Genomics, 2019, 29, 39-47.	1.5	21
49	CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control. Drug Metabolism and Drug Interactions, 2013, 28, 59-63.	0.3	20
50	Determining Allele-Specific Protein Expression (ASPE) Using a Novel Quantitative Concatamer Based Proteomics Method. Journal of Proteome Research, 2018, 17, 3606-3612.	3.7	20
51	CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects. Pharmacogenetics and Genomics, 2013, 23, 228-231.	1.5	19
52	Serum Response Factor Activation by Muscarinic Receptors via RhoA. Journal of Biological Chemistry, 2002, 277, 40789-40798.	3.4	18
53	Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus. Pharmacogenetics and Genomics, 2016, 26, 197-207.	1.5	18
54	Interactions Between Regulatory Variants in CYP7A1 (Cholesterol 7Î±-Hydroxylase) Promoter and Enhancer Regions Regulate CYP7A1 Expression. Circulation Genomic and Precision Medicine, 2018, 11, e002082.	3.6	18

#	Article	IF	Citations
55	Polymorphisms of the SAMHD1 Gene Are Not Associated with the Infection and Natural Control of HIV Type 1 in Europeans and African-Americans. AIDS Research and Human Retroviruses, 2012, 28, 1565-1573.	1.1	17
56	Allele-Selective Transcriptome Recruitment to Polysomes Primed for Translation: Protein-Coding and Noncoding RNAs, and RNA Isoforms. PLoS ONE, 2015, 10, e0136798.	2.5	15
57	SIRT1 Gene SNP rs932658 Is Associated With Medication-Related Osteonecrosis of the Jaw. Journal of Bone and Mineral Research, 2020, 36, 347-356.	2.8	14
58	Intronic SNP in ESR1 encoding human estrogen receptor alpha is associated with brain ESR1 mRNA isoform expression and behavioral traits. PLoS ONE, 2017, 12, e0179020.	2.5	14
59	Basal signaling activity of human dopamine D2L receptor demonstrated with an ecdysone-inducible mammalian expression system. Journal of Neuroscience Methods, 2000, 94, 217-225.	2.5	13
60	Estimation of Sobol's sensitivity indices under generalized linear models. Communications in Statistics - Theory and Methods, 2018, 47, 5163-5195.	1.0	13
61	Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotypeâ€Derived Activity Scores. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 678-685.	2.5	13
62	CYP2C9 Promoter Variable Number Tandem Repeat Polymorphism Regulates mRNA Expression in Human Livers. Drug Metabolism and Disposition, 2012, 40, 884-891.	3.3	11
63	Co-expression of drug metabolizing cytochrome P450 enzymes and estrogen receptor alpha (ESR1) in human liver: racial differences and the regulatory role of ESR1. Drug Metabolism and Personalized Therapy, 2021, 36, 205-214.	0.6	11
64	Regulation of cholesteryl ester transfer protein expression by upstream polymorphisms. Pharmacogenetics and Genomics, 2015, 25, 394-401.	1.5	10
65	Regulatory Variants Modulate Protein Kinase C Î± (PRKCA) Gene Expression in Human Heart. Pharmaceutical Research, 2017, 34, 1648-1657.	3.5	10
66	Cis-acting regulatory elements regulating CYP3A4 transcription in human liver. Pharmacogenetics and Genomics, 2020, 30, 107-116.	1.5	9
67	Regulation of CYP3A4 and CYP3A5 by a lncRNA: a potential underlying mechanism explaining the association between CYP3A4*1G and CYP3A metabolism. Pharmacogenetics and Genomics, 2022, 32, 16-23.	1.5	9
68	Calmodulin interaction with peptides from G-protein coupled receptors measured with S-Tag labeling. Biochemical and Biophysical Research Communications, 2005, 333, 390-395.	2.1	8
69	Analyzing allele specific RNA expression using mixture models. BMC Genomics, 2015, 16, 566.	2.8	8
70	ESR1 ChIP-Seq Identifies Distinct Ligand-Free ESR1 Genomic Binding Sites in Human Hepatocytes and Liver Tissue. International Journal of Molecular Sciences, 2021, 22, 1461.	4.1	8
71	Genomeâ€wide Association Study Identified Chromosome 8 Locus Associated with Medicationâ€Related Osteonecrosis of the Jaw. Clinical Pharmacology and Therapeutics, 2021, 110, 1558-1569.	4.7	8
72	XRCC1â€mediated DNA repair is associated with progressionâ€free survival of multiple myeloma patients after autologous stem cell transplant. Molecular Carcinogenesis, 2019, 58, 2327-2339.	2.7	7

#	Article	IF	Citations
73	Cytochrome P450 3A4 (CYP3A4) protein quantification using capillary western blot technology and total protein normalization. Journal of Pharmacological and Toxicological Methods, 2021, 112, 107117.	0.7	7
74	Functional CYP3A variants affecting tacrolimus trough blood concentrations in Chinese renal transplant recipients. Pharmacogenomics Journal, 2021, 21, 376-389.	2.0	5
75	Conditional entropy in variation-adjusted windows detects selection signatures associated with expression quantitative trait loci (eQTLs). BMC Genomics, 2015, 16, S8.	2.8	3
76	Calmodulin Binding to Peptides Derived from the i3 Loop of Muscarinic Receptors. Pharmaceutical Research, 2006, 23, 647.	3.5	2
77	A Prospective, Double-Blinded, Observational Clinical Cohort Study of the Association Between Tacrolimus Exposure and CYP3A4, CYP3A5 Genotypes in Adult Hematopoietic Stem Cell Transplant Recipients. Biology of Blood and Marrow Transplantation, 2013, 19, S380.	2.0	1
78	Response to paper by Kelly et al â€œThe opioid receptor pharmacology of GSK1521498 compared to other ligands with different effects on compulsive reward-related behaviorsâ€•published in Psychopharmacology 232, 305â€“314, 2014. Psychopharmacology, 2015, 232, 1493-1494.	3.1	0
79	Dissecting CYP3A interactome to understand the causes of CYP3A variability. Drug Metabolism and Pharmacokinetics, 2018, 33, S83-S84.	2.2	0
80	Association of Regulatory Genetic Variants for Protein Kinase CÎ± with Mortality and Drug Efficacy in Patients with Heart Failure. Cardiovascular Drugs and Therapy, 2019, 33, 693-700.	2.6	0
81	Response to the Comments on â€œDetermining Allele-Specific Protein Expression (ASPE) Using a Novel Quantitative Concatamer Proteomics Methodâ€• Journal of Proteome Research, 2019, 18, 1458-1459.	3.7	0
82	Transcriptional Regulation of Carboxylesterase 1 in Human Liver: Role of the Nuclear Receptor Subfamily 1 Group H Member 3 and Its Splice Isoforms. Drug Metabolism and Disposition, 2022, 50, 43-48.	3.3	0
83	Common alleles in human Nâ€acetyltransferase 1 (NAT1 *10 and *11) increase enzyme activity via distinct mechanisms and associate with sulfamethoxazole induced hypersensitivity. FASEB Journal, 2011, 25, .	0.5	0
84	CYP2D6 expression is regulated by polymorphisms that affect splicing and trancription: new biomarkers for CYP2D6 activity. FASEB Journal, 2013, 27, 663.6.	0.5	0
85	A comparison of genetic sampling methodologies for candidate-gene analyses. Journal of Translational Science, 2019, 5, .	0.2	0
86	Abstract 15986: Plasma Microrna Profiling Reveals Potential Biomarkers of Thiazide Response. Circulation, 2020, 142, .	1.6	0